^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tigatuzumab (CS-1008)

    i
    Other names: CS-1008 , TRA 8, CS 1008
    Associations

    News

    Trials
    Company:
    Daiichi Sankyo
    Drug class:
    TRAIL R2 agonist
    Related drugs:
    Associations

    News

    Trials
    8ms
    Identification and validation of an immune-relevant risk signature predicting survival outcome and immune infiltration in uveal melanoma. (PubMed, Int Ophthalmol)
    The identified immune risk signature was demonstrated to be associated with the favorable immune infiltration, prognosis and immunotherapeutic efficacy, which may provide clues for survival evaluation and immune treatment.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    tigatuzumab (CS-1008)